Related Experiment Video
Updated: Jun 28, 2026

Pre-Chiasmatic, Single Injection of Autologous Blood to Induce Experimental Subarachnoid Hemorrhage in a Rat Model
Published on: June 18, 2021
Recurrent perimesencephalic subarachnoid hemorrhage during antithrombotic therapy
H Bart van der Worp1, Susanne Fonville, Lino M P Ramos
1Department of Neurology, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Heidelberglaan 100, 3584 Utrecht, The Netherlands. h.b.vanderworp@umcutrecht.nl
Antithrombotic therapy in patients with perimesencephalic hemorrhage may trigger rebleeding, even without aneurysms. Careful risk-benefit assessment is crucial before initiating such treatments in these cases.
Area of Science:
- Neurology
- Vascular Neurology
Background:
- Non-aneurysmal perimesencephalic hemorrhage typically has a low risk of spontaneous rebleeding.
- This perceived safety may influence clinical decisions regarding antithrombotic therapy.
Observation:
- A case report details a 57-year-old woman with perimesencephalic hemorrhage.
- She received antithrombotic therapy (carbasalate calcium and heparin) for acute coronary syndrome.
Findings:
- Three days after initiating antithrombotic therapy, the patient experienced recurrent perimesencephalic hemorrhage.
- This complication led to hydrocephalus, decreased consciousness, and ultimately, death.
Implications:
- Early anticoagulant therapy following perimesencephalic hemorrhage poses a risk of rebleeding.
- Careful consideration of risks versus benefits of antithrombotic therapy is essential in patients with negative CT angiography for perimesencephalic hemorrhage.
Related Concept Videos
Hemorrhagic Stroke l: Introduction
Hemorrhagic Stroke ll: Pathophysiology
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Aneurysm III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins

